- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 18.08. | Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 3 | GlobeNewswire (USA) | ||
| 13.08. | Zenas BioPharma GAAP EPS of -$1.77 misses by $0.65, revenue of $1M | 2 | Seeking Alpha | ||
| 13.08. | Zenas BioPharma, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 13.08. | Zenas BioPharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 17.07. | Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 17.06. | Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 11.06. | Zenas BioPharma to Present at the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit | 1 | GlobeNewswire (USA) | ||
| ZENAS BIOPHARMA Aktie jetzt für 0€ handeln | |||||
| 03.06. | H.C. Wainwright bestätigt Kaufempfehlung für Zenas Biopharma nach Studienerfolg | 3 | Investing.com Deutsch | ||
| 03.06. | H.C. Wainwright reiterates Zenas Biopharma stock rating at buy | 1 | Investing.com | ||
| 03.06. | Zenas BioPharma reports positive phase 3 trial results for obexelimab | 2 | Investing.com | ||
| 03.06. | Zenas BioPharma Announces Data from the Registrational Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD), Simultaneously Presented at the EULAR 2026 Congress and Published in the New England Journal of Medicine | 2 | GlobeNewswire (USA) | ||
| 28.05. | Zenas BioPharma Announces Submission of Biologics License Application (BLA) to U.S. FDA for Obexelimab in IgG4-RD | 585 | GlobeNewswire (Europe) | - BLA submission based on positive results from Phase 3 INDIGO trial - WALTHAM, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. ("Zenas," "Zenas BioPharma" or the "Company") (Nasdaq:... ► Artikel lesen | |
| 19.05. | Zenas BioPharma präsentiert Studiendaten zu Obexelimab auf dem EULAR-Kongress | 1 | Investing.com Deutsch | ||
| 19.05. | Zenas BioPharma to present obexelimab trial data at EULAR congress | 3 | Investing.com | ||
| 19.05. | Zenas BioPharma Announces Upcoming Presentation of Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) at EULAR 2026 Congress | 346 | GlobeNewswire (Europe) | - Safety and efficacy results from the Phase 3 INDIGO trial to be presented by Emanuel Della Torre, M.D., Ph.D., on Thursday June 4, 2026, at 2:45 PM GMT - WALTHAM, Mass., May 19, 2026 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| 18.05. | Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 13.05. | Zenas BioPharma Announces First Subject Dosed in Phase 1 Clinical Trial of ZB021, a Novel, Potentially Best-in-Class Oral IL-17AA/AF Inhibitor | 302 | GlobeNewswire (Europe) | - Phase 1 trial designed to evaluate the safety, tolerability, and pharmacokinetic properties of ZB021 in healthy volunteers and to establish proof-of-concept in patients with plaque psoriasis - -... ► Artikel lesen | |
| 13.05. | Zenas BioPharma, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 13.05. | Zenas BioPharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 13.05. | Zenas BioPharma GAAP EPS of -$1.46 beats by $0.22 | 2 | Seeking Alpha |
1 2 3 Weiter >>
46 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 2,798 | +0,76 % | Katalysator voraus: Valneva (ISIN: FR0004056851) setzt auf Q3-Shigella-Daten | ||
| AMGEN | 371,90 | -0,35 % | Amgen: Tezspire Demonstrates Positive Phase 3 Results In Eosinophilic Esophagitis Across Both Co-primary And All Key Secondary Endpoints | Statistically Significant and Clinically Meaningful Disease and Symptom Improvements Compared to Placebo Maintained Through Week 52
Efficacy in a Third Epithelial-Driven... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 682,40 | -0,41 % | Veeva Systems: Veeva Vault CRM Selected by Regeneron | Leading biopharma company selects agentic CRM for life sciences to generate Commercial EvidencePLEASANTON, Calif., Aug. 25, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced... ► Artikel lesen | |
| VIKING THERAPEUTICS | 27,850 | +0,36 % | Viking Therapeutics Has $502 Million in Cash and 1 Big Catalyst Left in 2026 -- Is That Enough? | ||
| TEMPUS AI | 55,25 | -0,04 % | Tempus AI (TEM) Jumped on Moderna's Melanoma Win. Did its $1.5B Personalis Acquisition Just Get Validated? | ||
| VIVORYON THERAPEUTICS | 1,125 | -0,88 % | Vivoryon Therapeutics N.V. to Hold its 2026 Annual General Meeting on September 29, 2026 | Vivoryon Therapeutics N.V. to Hold its 2026 Annual General Meeting on September 29, 2026
Halle (Saale) / Munich, Germany, August 18, 2026 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7)... ► Artikel lesen | |
| BIOMARIN PHARMACEUTICAL | 55,62 | -1,31 % | Piper Sandler reiterates Overweight on BioMarin stock at $88 target | ||
| SAREPTA THERAPEUTICS | 18,240 | +1,33 % | Biotech-Player: Zelltherapie als Comeback-Story im Milliardenmarkt. Neue Ideen nach Corona von BioNTech, Qiagen und Biotech AG | ||
| ARROWHEAD PHARMACEUTICALS | 73,36 | -3,30 % | Could Arrowhead Pharmaceuticals (ARWR)'s Plozasiran Become the Catalyst for a Major Stock Re-rating? | ||
| TRAWS PHARMA | 0,590 | 0,00 % | Traws Pharma, Inc.: Traws Pharma Reports Q2 2026 Financial Results and Provides Business Highlights | Advancing tivoxavir marboxil toward MHRA resubmission in Q3 2026 with a revised toxicology package, supporting initiation of the Phase 2a human influenza Challenge studyCompleted the April 2026 private... ► Artikel lesen | |
| VERASTEM | 6,280 | +0,71 % | Mizuho lowers Verastem stock price target on valuation to $13 | ||
| INSMED | 102,44 | +0,14 % | Insmed's BRINSUPRI Wins Japan Approval For Treatment Of Non-Cystic Fibrosis Bronchiectasis | WASHINGTON (dpa-AFX) - Monday, Insmed Inc. (INSM) announced that Japan's Ministry of Health, Labour and Welfare has approved BRINSUPRI, or brensocatib 25-mg tablet, for the treatment of non-cystic... ► Artikel lesen | |
| ZAI LAB LTD ADR | 23,000 | +1,77 % | ZAI LAB (09688): 2026 INTERIM REPORT | ||
| TRINITY BIOTECH | 9,700 | +0,31 % | Trinity Biotech plc: Trinity Biotech Provides Diagnostics Business, Transformation And Corporate Update | - Continued execution of transformation strategy drives commercial, manufacturing and pipeline progress - PrePsia patent portfolio expands to nine granted U.S. and European patents - Company issues... ► Artikel lesen | |
| VOYAGER THERAPEUTICS | 2,990 | -2,03 % | H.C. Wainwright reiterates Voyager Therapeutics stock rating at buy |
ZENAS BIOPHARMA INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,050 (-0,16 %) liegt der Kurs bei 31,220 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ZENAS BIOPHARMA INC finden Sie auf Wallstreet Online.